日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma

Linvoseltamab 与真实世界中国际骨髓瘤工作组标准治疗方案在三线抗肿瘤治疗后复发/难治性多发性骨髓瘤中的比较

Kumar, Shaji; Jagannath, Sundar; Weisel, Katja C; Rosiñol, Laura; Leleu, Xavier; Dimopoulos, Meletios-Athanasios; Kastritis, Efstathios; Siegel, David S; Monge, Jorge; Du, Juan; de la Rubia, Javier; Asensi Cantó, Pedro; Lee, Jae Hoon; Mateos, María-Victoria; Puertas, Borja; Gozzetti, Alessandro; Dytfeld, Dominik; Ocio, Enrique M; Blade, Joan; Ozaki, Shuji; Beksac, Meral; Escalante, Fernando; Nagaraj, Madhu; Hassan, Rafla; Bonar, Nicolle; Spin, Paul; Shokoohi, Mostafa; Siddiqui, Muhaimen; Wang, Di; Hou, Kevin; West, Michael E D; Hampp, Christian; Green, Jeannette; Humblet, Olivier; Breskin, Alexander; Harnett, James; Ge, Wenzhen; Sobel, Rachel E; Jalbert, Jessica J; Kroog, Glenn S; Rodriguez Lorenc, Karen; Ma, Qiufei; Durie, Brian G M

8-11 year results of LARS augmented hamstring in anterior cruciate ligament reconstruction surgery: Incidence of synovitis and failures

LARS增强腘绳肌腱在前交叉韧带重建手术中的8-11年随访结果:滑膜炎和手术失败的发生率

Qurashi, Sol; Ashaia, Wagdy; Maier, Janna; Ridley, William; Chao, Tat; Jassim, Muhaimen; Aktas, Sam; Ayeni, Femi E; Narulla, Raj

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis

利用历史数据和倾向评分匹配分析,在伴有IDH2突变的复发/难治性急性髓系白血病中,与标准治疗相比,enasidenib可改善生存率

de Botton, Stéphane; Brandwein, Joseph M; Wei, Andrew H; Pigneux, Arnaud; Quesnel, Bruno; Thomas, Xavier; Legrand, Ollivier; Recher, Christian; Chantepie, Sylvain; Hunault-Berger, Mathilde; Boissel, Nicolas; Nehme, Salem A; Frattini, Mark G; Tosolini, Alessandra; Marion-Gallois, Roland; Wang, Jixian J; Cameron, Chris; Siddiqui, Muhaimen; Hutton, Brian; Milkovich, Gary; Stein, Eytan M